Thais Sielecki
Directeur des opérations chez Polycore Therapeutics, Inc.
Profil
Thais Sielecki is currently working as the Treasurer at Cytokine PharmaSciences, Inc. since 2009.
Dr. Sielecki is also currently serving as the Chief Operating Officer at Polycore Therapeutics, Inc. Dr. Sielecki previously worked as a Principal at DuPont Merck Pharmaceutical Co. Dr. Sielecki holds a doctorate degree from Colorado State University.
Postes actifs de Thais Sielecki
| Sociétés | Poste | Début |
|---|---|---|
Cytokine PharmaSciences, Inc.
 Cytokine PharmaSciences, Inc. Pharmaceuticals: MajorHealth Technology Cytokine PharmaSciences, Inc. operates as a biopharmaceutical company. It develops and manufactures drug delivery products. The firm involves in developing controlled-release drug delivery products in the area of women's health; and small molecule therapeutics in the areas of autoimmune diseases, anti-inflammation, and cancer. The company was founded in June 1999 and is headquartered in Conshohocken, PA. | Treasurer | 01/04/2003 |
Polycore Therapeutics, Inc.
 Polycore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Polycore Therapeutics, Inc. is a biopharmaceutical company that develops treatments for patients with neurodegenerative disorders. The company is based in Philadelphia, PA. Polycore Therapeutics was founded by Sandhya Kortagere, Jim Harris. The company is currently conducting preclinical studies for its lead compound, PCT-3012, a novel small molecule for the treatment of Parkinson's motor symptoms and in patients with early- to mid-stage Parkinson's disease. The CEO is Kelly Beck. | Directeur des opérations | - |
Anciens postes connus de Thais Sielecki
| Sociétés | Poste | Fin |
|---|---|---|
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Corporate Officer/Principal | - |
Formation de Thais Sielecki
| Colorado State University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Cytokine PharmaSciences, Inc.
Cytokine PharmaSciences, Inc. Pharmaceuticals: MajorHealth Technology Cytokine PharmaSciences, Inc. operates as a biopharmaceutical company. It develops and manufactures drug delivery products. The firm involves in developing controlled-release drug delivery products in the area of women's health; and small molecule therapeutics in the areas of autoimmune diseases, anti-inflammation, and cancer. The company was founded in June 1999 and is headquartered in Conshohocken, PA. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
Polycore Therapeutics, Inc.
Polycore Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Polycore Therapeutics, Inc. is a biopharmaceutical company that develops treatments for patients with neurodegenerative disorders. The company is based in Philadelphia, PA. Polycore Therapeutics was founded by Sandhya Kortagere, Jim Harris. The company is currently conducting preclinical studies for its lead compound, PCT-3012, a novel small molecule for the treatment of Parkinson's motor symptoms and in patients with early- to mid-stage Parkinson's disease. The CEO is Kelly Beck. | Health Technology |
